JP Morgan maintains TransMedics Group at Neutral, raises price target to $85 from $73

JP Morgan kept its 'Neutral' rating on TransMedics Group but raised its price target to $85 from $73, a 16.4% increase. The new target suggests a 3.7% downside from the Nov 6 close of $88.24. Other recent analyst targets for the company range from $110 to $120.

Original reporting
Published Nov 7, 2026, 2:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 7, 2026, 2:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
JP Morgan maintains TransMedics Group at Neutral, raises price target to $85 from $73 — source image
Decision brief

The 30-second read

Med
01

Why it matters

The target increase may attract buyers seeking upside, but the effect is modest without a catalyst.

02

Market read

A modest analyst upgrade that could generate short‑term buying pressure.

03

What to watch

Potential regulatory or reimbursement risks not addressed in the note.

Relevance 6/10Novelty 6/10Timing: today

Background

Analyst price target updates are routine but can influence short‑term trading.

Market effects

May lift sentiment in the medical device sector.

Limited to US markets where TMED trades.

Low; impact confined to the company and its niche sector.

Counterpoint

Target raises can be premature; price may already reflect optimism.

Key entities

  • JP Morgan

    Provided the price target upgrade.

  • TransMedics Group

    Subject of the price target change.

Related articles

Med

TransMedics revenue up 41% to USD 203M in Q3 2026

TransMedics reported Q3 2026 revenue of $203M, up 41% YoY, driven by increased organ transplant volumes and logistics services. Gross margin was 58.5%, with operating income of $28.1M. The company cited growth catalysts like ENHANCE Heart Part B and DENOVO Lung, and plans for European expansion. Net income fell to $17.1M, or $0.46 per share, from $24.3M, or $0.66 per share, a year earlier.

$TMDXMed

TransMedics Group Q3 Earnings Call Highlights

TransMedics Group reported Q3 product gross margin at 79.2% and service gross margin at 32.2%. Adjusted net income was $18.9M, or $0.51 per share, with $493M in cash. The company completed ENHANCE Heart Part A enrollment and plans submissions in 2027. It also targets European expansion and kidney platform trials in 2027, maintaining its full-year adjusted operating margin outlook of 12.5% to 14%.